Moteur de recherche d’entreprises européennes
Financement de l’UE (6 003 930 €) : Co-création et mise en œuvre d’une intervention pour améliorer la compréhension des effets tardifs des tests et des soins de soutien non satisfaits des survivants … Hor19/05/2025 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Co-création et mise en œuvre d’une intervention pour améliorer la compréhension des effets tardifs des tests et des soins de soutien non satisfaits des survivants de l’AJA en utilisant la réalité étendue.
"CHALLENGE: Adolescence and early adulthood are critical stages for development. A diagnosis of a life-threating disease like cancer in adolescents and young adults (AYAs), coupled with immediate and late effects of treatment, force AYAs to face mortality early in life. Testicular Cancer (TC) is the most diagnosed cancer in AYAs assigned male at birth aged 15-39 years. The incidence of TC has doubled over the last four decades, with highest incidence rates in individuals of European ancestry. Interventions to educate and support AYA TC survivors, and reduce symptom burden and late effects of TC treatment should be prioritised. SOLUTION: Project TRANSCEND-XR will ethically co-create, test, and scale up in real-life settings an innovative digital intervention to increase AYA TC survivors’ knowledge of the late effects of TesticulaR cANcer treatment and address their unmet Supportive CarE NeeDs using eXtended Reality. PLAN: TRANSCEND-XR will ensure that (i) the needs of AYA TC survivors, their care partners, and healthcare professionals are explored and disparities addressed; (ii) the TRANSCEND-XR intervention is robustly and ethically co-created, refined, and validated; (iii) there is understanding of intervention effectiveness, cost-effectiveness, process of delivery, and what AYA TC survivors ethically value about it in real-life settings. Evidence-based plans to translate knowledge into practice and policy, exploit outputs, and sustain TRANSCEND-XR in long-term, robust governance and effective patient and public involvement are established. IMPACT: TRANSCEND-XR will revolutionise the understanding and management of late effects from TC treatment among AYA survivors, improving their quality of life, throughout Europe. It will serve as a proof of concept for ethically developing, evaluating, and implementing immersive educational digital health solutions to support AYA cancer survivors. This action is part of the Cancer Mission cluster of projects on “Quality of life (AYA)""."
| ACADEMISCH ZIEKENHUIS GRONINGEN | 214 514 € |
| Association Europeenne des Ligues Contre le Cancer ASBL | 149 000 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 230 685 € |
| Fondazione Irccs Istituto Nazionale DEI Tumori | 195 813 € |
| Fundtoinnovate Ltd. | 474 335 € |
| Institut Gustave Roussy | 1 004 688 € |
| Khora ApS | 626 006 € |
| Predictby Research And Consulting SL | 202 500 € |
| SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET | 158 825 € |
| The Adelaide & Meath Hospital Dublin Incorporating the National Children's Hospital | 74 006 € |
| The Queen's University of Belfast | 613 999 € |
| The Royal Marsden National Health Service Trust | 203 780 € |
| Universidade Catolica Portuguesa | 421 700 € |
| University College Cork - National University of Ireland, Cork | 1 247 205 € |
| Univerzita Komenskeho V Bratislave | 186 875 € |
https://cordis.europa.eu/project/id/101214413
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ACADEMISCH ZIEKENHUIS GRONINGEN - Financement de l’UE (6 003 930 €) : Co-création et mise en œuvre d’une intervention pour améliorer la compréhension des effets tardifs des tests et des soins de soutien non satisfaits des survivants …"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
